What is the projected market valuation for the Gastrointestinal Testing Panels Market in 2035?

The projected market valuation for the Gastrointestinal Testing Panels Market in 2035 is 1.513 USD Billion. Read More

What was the market valuation for the Gastrointestinal Testing Panels Market in 2024?

The overall market valuation for the Gastrointestinal Testing Panels Market was 0.57 USD Billion in 2024. Read More

What is the expected CAGR for the Gastrointestinal Testing Panels Market during the forecast period 2025 - 2035?

The expected CAGR for the Gastrointestinal Testing Panels Market during the forecast period 2025 - 2035 is 9.28%. Read More

Which companies are considered key players in the Gastrointestinal Testing Panels Market?

Key players in the Gastrointestinal Testing Panels Market include Thermo Fisher Scientific, Abbott Laboratories, Roche Diagnostics, and Danaher Corporation. Read More

How does the market segment for patient population break down in terms of valuation?

The patient population segment includes Cancer Patients valued at 0.15 USD Billion and Chronic Disease Patients valued at 0.2 USD Billion. Read More

What is the valuation range for the Fecal Immunochemical Test (FIT) segment?

The valuation range for the Fecal Immunochemical Test (FIT) segment is between 0.2 and 0.5 USD Billion. Read More

What sample types are analyzed in the Gastrointestinal Testing Panels Market?

Sample types analyzed in the market include Blood, Stool, and Urine, with Stool valued at 0.2 USD Billion. Read More

What is the valuation range for the C-reactive Protein biomarker segment?

The valuation range for the C-reactive Protein biomarker segment is between 0.1 and 0.3 USD Billion. Read More

How does the market for older adults compare to other patient populations?

The market for older adults is valued between 0.07 and 0.15 USD Billion, indicating a smaller segment compared to Cancer and Chronic Disease Patients. Read More

Gastrointestinal Testing Panels Market

Q: What are the main test types included in the Gastrointestinal Testing Panels Market?

Main test types in the market include Fecal Occult Blood Test (FOBT), Fecal Immunochemical Test (FIT), and Stool DNA Test. Read More

Gastrointestinal Testing Panels Market Research Report: Size, Share, Trend Analysis By Test Type (Fecal Occult Blood Test (FOBT), Fecal Immunochemical Test (FIT), Stool DNA Test, Colonoscopy, Upper Endoscopy), By Biomarker (Hemoglobin, Hemoglobin A1C, C-reactive Protein, CA 125, CA 19-9), By Patient Population (Cancer Patients, Chronic Disease Patients, Pregnant Women, Children, Older Adults), By Sample Type (Blood, Stool, Urine, Tissue, Saliva) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

9.28%

2024 Market Size

$ 0.57 Billion

2035 Market Size

$ 1.51 Billion

Healthcare ● Updated April 2026 Report ID: MRFR/HC/25917-HCR | Pages: 128 | Author: Nidhi Mandole, Kinjoll Dey

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Test Type (USD Billion)
  1. 4.1.1 Fecal Occult Blood Test (FOBT)
  2. 4.1.2 Fecal Immunochemical Test (FIT)
  3. 4.1.3 Stool DNA Test
  4. 4.1.4 Colonoscopy
  5. 4.1.5 Upper Endoscopy
2. 4.2 Healthcare, BY Biomarker (USD Billion)
  1. 4.2.1 Hemoglobin
  2. 4.2.2 Hemoglobin A1C
  3. 4.2.3 C-reactive Protein
  4. 4.2.4 CA 125
  5. 4.2.5 CA 19-9
3. 4.3 Healthcare, BY Patient Population (USD Billion)
  1. 4.3.1 Cancer Patients
  2. 4.3.2 Chronic Disease Patients
  3. 4.3.3 Pregnant Women
  4. 4.3.4 Children
  5. 4.3.5 Older Adults
4. 4.4 Healthcare, BY Sample Type (USD Billion)
  1. 4.4.1 Blood
  2. 4.4.2 Stool
  3. 4.4.3 Urine
  4. 4.4.4 Tissue
  5. 4.4.5 Saliva
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Thermo Fisher Scientific (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Abbott Laboratories (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Roche Diagnostics (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Danaher Corporation (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Siemens Healthineers (DE)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Bio-Rad Laboratories (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 F. Hoffmann-La Roche AG (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Meridian Bioscience (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Genomic Health (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TEST TYPE
4. 6.4 US MARKET ANALYSIS BY BIOMARKER
5. 6.5 US MARKET ANALYSIS BY PATIENT POPULATION
6. 6.6 US MARKET ANALYSIS BY SAMPLE TYPE
7. 6.7 CANADA MARKET ANALYSIS BY TEST TYPE
8. 6.8 CANADA MARKET ANALYSIS BY BIOMARKER
9. 6.9 CANADA MARKET ANALYSIS BY PATIENT POPULATION
10. 6.10 CANADA MARKET ANALYSIS BY SAMPLE TYPE
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY TEST TYPE
13. 6.13 GERMANY MARKET ANALYSIS BY BIOMARKER
14. 6.14 GERMANY MARKET ANALYSIS BY PATIENT POPULATION
15. 6.15 GERMANY MARKET ANALYSIS BY SAMPLE TYPE
16. 6.16 UK MARKET ANALYSIS BY TEST TYPE
17. 6.17 UK MARKET ANALYSIS BY BIOMARKER
18. 6.18 UK MARKET ANALYSIS BY PATIENT POPULATION
19. 6.19 UK MARKET ANALYSIS BY SAMPLE TYPE
20. 6.20 FRANCE MARKET ANALYSIS BY TEST TYPE
21. 6.21 FRANCE MARKET ANALYSIS BY BIOMARKER
22. 6.22 FRANCE MARKET ANALYSIS BY PATIENT POPULATION
23. 6.23 FRANCE MARKET ANALYSIS BY SAMPLE TYPE
24. 6.24 RUSSIA MARKET ANALYSIS BY TEST TYPE
25. 6.25 RUSSIA MARKET ANALYSIS BY BIOMARKER
26. 6.26 RUSSIA MARKET ANALYSIS BY PATIENT POPULATION
27. 6.27 RUSSIA MARKET ANALYSIS BY SAMPLE TYPE
28. 6.28 ITALY MARKET ANALYSIS BY TEST TYPE
29. 6.29 ITALY MARKET ANALYSIS BY BIOMARKER
30. 6.30 ITALY MARKET ANALYSIS BY PATIENT POPULATION
31. 6.31 ITALY MARKET ANALYSIS BY SAMPLE TYPE
32. 6.32 SPAIN MARKET ANALYSIS BY TEST TYPE
33. 6.33 SPAIN MARKET ANALYSIS BY BIOMARKER
34. 6.34 SPAIN MARKET ANALYSIS BY PATIENT POPULATION
35. 6.35 SPAIN MARKET ANALYSIS BY SAMPLE TYPE
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY TEST TYPE
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY BIOMARKER
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY PATIENT POPULATION
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY SAMPLE TYPE
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY TEST TYPE
42. 6.42 CHINA MARKET ANALYSIS BY BIOMARKER
43. 6.43 CHINA MARKET ANALYSIS BY PATIENT POPULATION
44. 6.44 CHINA MARKET ANALYSIS BY SAMPLE TYPE
45. 6.45 INDIA MARKET ANALYSIS BY TEST TYPE
46. 6.46 INDIA MARKET ANALYSIS BY BIOMARKER
47. 6.47 INDIA MARKET ANALYSIS BY PATIENT POPULATION
48. 6.48 INDIA MARKET ANALYSIS BY SAMPLE TYPE
49. 6.49 JAPAN MARKET ANALYSIS BY TEST TYPE
50. 6.50 JAPAN MARKET ANALYSIS BY BIOMARKER
51. 6.51 JAPAN MARKET ANALYSIS BY PATIENT POPULATION
52. 6.52 JAPAN MARKET ANALYSIS BY SAMPLE TYPE
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY TEST TYPE
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY BIOMARKER
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY PATIENT POPULATION
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY SAMPLE TYPE
57. 6.57 MALAYSIA MARKET ANALYSIS BY TEST TYPE
58. 6.58 MALAYSIA MARKET ANALYSIS BY BIOMARKER
59. 6.59 MALAYSIA MARKET ANALYSIS BY PATIENT POPULATION
60. 6.60 MALAYSIA MARKET ANALYSIS BY SAMPLE TYPE
61. 6.61 THAILAND MARKET ANALYSIS BY TEST TYPE
62. 6.62 THAILAND MARKET ANALYSIS BY BIOMARKER
63. 6.63 THAILAND MARKET ANALYSIS BY PATIENT POPULATION
64. 6.64 THAILAND MARKET ANALYSIS BY SAMPLE TYPE
65. 6.65 INDONESIA MARKET ANALYSIS BY TEST TYPE
66. 6.66 INDONESIA MARKET ANALYSIS BY BIOMARKER
67. 6.67 INDONESIA MARKET ANALYSIS BY PATIENT POPULATION
68. 6.68 INDONESIA MARKET ANALYSIS BY SAMPLE TYPE
69. 6.69 REST OF APAC MARKET ANALYSIS BY TEST TYPE
70. 6.70 REST OF APAC MARKET ANALYSIS BY BIOMARKER
71. 6.71 REST OF APAC MARKET ANALYSIS BY PATIENT POPULATION
72. 6.72 REST OF APAC MARKET ANALYSIS BY SAMPLE TYPE
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY TEST TYPE
75. 6.75 BRAZIL MARKET ANALYSIS BY BIOMARKER
76. 6.76 BRAZIL MARKET ANALYSIS BY PATIENT POPULATION
77. 6.77 BRAZIL MARKET ANALYSIS BY SAMPLE TYPE
78. 6.78 MEXICO MARKET ANALYSIS BY TEST TYPE
79. 6.79 MEXICO MARKET ANALYSIS BY BIOMARKER
80. 6.80 MEXICO MARKET ANALYSIS BY PATIENT POPULATION
81. 6.81 MEXICO MARKET ANALYSIS BY SAMPLE TYPE
82. 6.82 ARGENTINA MARKET ANALYSIS BY TEST TYPE
83. 6.83 ARGENTINA MARKET ANALYSIS BY BIOMARKER
84. 6.84 ARGENTINA MARKET ANALYSIS BY PATIENT POPULATION
85. 6.85 ARGENTINA MARKET ANALYSIS BY SAMPLE TYPE
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TEST TYPE
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY BIOMARKER
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT POPULATION
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY SAMPLE TYPE
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TEST TYPE
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY BIOMARKER
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY PATIENT POPULATION
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY SAMPLE TYPE
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TEST TYPE
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY BIOMARKER
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY PATIENT POPULATION
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY SAMPLE TYPE
99. 6.99 REST OF MEA MARKET ANALYSIS BY TEST TYPE
100. 6.100 REST OF MEA MARKET ANALYSIS BY BIOMARKER
101. 6.101 REST OF MEA MARKET ANALYSIS BY PATIENT POPULATION
102. 6.102 REST OF MEA MARKET ANALYSIS BY SAMPLE TYPE
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY TEST TYPE, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY TEST TYPE, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY BIOMARKER, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY BIOMARKER, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY PATIENT POPULATION, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY PATIENT POPULATION, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY SAMPLE TYPE, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY SAMPLE TYPE, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.2.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.3.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.3.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.4.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.4.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.5.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.5.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.6.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.6.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.7.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.7.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.8.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.8.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.9.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.9.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.10.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.10.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.11.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.11.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.12.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.12.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.13.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.13.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.14.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.14.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.15.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.15.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.16.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.16.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.17.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.17.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.18.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.18.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.19.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.19.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.20.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.20.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.21.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.21.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.22.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.22.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.23.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.23.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.24.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.24.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.25.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.25.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.26.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.26.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.27.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.27.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.28.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.28.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.29.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.29.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.30.3 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  4. 7.30.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Gastrointestinal Testing Panels Market Segmentation

Gastrointestinal Testing Panels Market By Test Type (USD Billion, 2025-2035)

Fecal Occult Blood Test (FOBT)
Fecal Immunochemical Test (FIT)
Stool DNA Test
Colonoscopy
Upper Endoscopy

Gastrointestinal Testing Panels Market By Biomarker (USD Billion, 2025-2035)

Hemoglobin
Hemoglobin A1C
C-reactive Protein
CA 125
CA 19-9

Gastrointestinal Testing Panels Market By Patient Population (USD Billion, 2025-2035)

Cancer Patients
Chronic Disease Patients
Pregnant Women
Children
Older Adults

Gastrointestinal Testing Panels Market By Sample Type (USD Billion, 2025-2035)

Blood
Stool
Urine
Tissue
Saliva

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”